A Phase I Study of TS-1 Plus Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer

References

• Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non—small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210–3218.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimen for advanced non-small cell lung cancer. N Eng J Med 2002; 346: 92–98.
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gor-bounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
   Google Scholar
• Hotta K, Matsu° K, Ueoka H, Kiura K, Tanabe M, Tani-moto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 3852–3859.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parkish P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543–3551.
   PubMed Web of Science ®Google Scholar
• Sirasaka T, Shimamoto Y, Ohsimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (5-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluoruracil by two biochemical modulators. Anti-Cancer Drugs 1996; 7: 548–557.
   PubMed Web of Science ®Google Scholar
• Tastumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effect of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987; 78: 748–755.
   PubMedGoogle Scholar
• van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, et al. Phase I clinical and pharmaco-kinetic study of oral 5-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18: 2772-2779.
   Google Scholar
• Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, et al. Plasma concentration of 5-fluorouracil and F-beta-alanine following oral administration of 5-1, a dihydropy-rimidine dehydrogenase inhibitory fluoroprymidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 2003; 89: 816–820.
   PubMed Web of Science ®Google Scholar
• Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001; 85: 939–943.
   PubMed Web of Science ®Google Scholar
• Ichinose Y, Yoshimori K, sakai H, Nakai Y, Sugiura T, Kawahara M, at al. S-1 plus cisplatin combination chemother-apy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004; 10: 7860-7864.
   Google Scholar
• R. Rosell, U. Gatzemeier, D. C. Betticher, U. Keppler, H. N. Macha, R. Pirker, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13: 1539–49.
   PubMed Web of Science ®Google Scholar
• Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnel M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–1756.
   PubMed Web of Science ®Google Scholar
• Ando Y, Minami H, Saka H, Sakai S, Shimokata K. Ad-justment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer 1997; 76: 1067–1071.
   PubMed Web of Science ®Google Scholar
• Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Shimizu Y, et al. A phase I study of 5-1 plus carboplatin in patients with non-small-cell lung cancer. Anti-Cancer Drugs 2007; 18: 471–476.
   PubMed Web of Science ®Google Scholar
• Decker DA, Drelichman A, Jacobs J Hoschner J, Kinzie J, Loh JJ, et al. Adjuvant chemotherapy with cis-diammin-odichloroplatinum II and 120-hour infusion 5-fluorouracil in the stage III and IV squamous cell carcinoma of the head and neck. Cancer (Phila) 1983; 51: 1353–1355.
   Google Scholar
• Kemeny N, Israel K, Niedzwiecki D, Chapman D, Botet J, Minsky B, et al. Randomized study of continuous infusion fluo-rouracil versus fluorouracil plus cisplatin in patients with metasta-tic colorectal cancer. J Clin Oncol 1990; 8: 313–318.
   PubMed Web of Science ®Google Scholar
• Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Nati Acad Sci USA 1986; 83: 8923-8925.
   Google Scholar
• Shirasaka T, Shimamoto Y, Ohshima H, Saito H, Fukushima M. Metabolic basis on the synergistic antitumor ac-tivities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167–172.
   PubMed Web of Science ®Google Scholar
• Kuroki M, Nakano S, MItsugi K, Ichinose I, Anzai K, Naka-mura M, et al. In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly es-tablished HST-1 human squamous-carcinoma cell line. Cancer Chemother Pharmacol 1992; 29: 273–6
   PubMed Web of Science ®Google Scholar